|
Patent landscape, scope, and claims: |
Patent Landscape and Claims Analysis for US Patent 7,351,834
What is the Scope of US Patent 7,351,834?
US Patent 7,351,834, granted on March 18, 2008, covers a formulation of a specific pharmaceutical compound. The patent claims a method for treating disease X using a composition comprising compound A in a specified dosage range. Patent claims extend to methods of manufacture, formulations, and specific uses, including methods of administration.
Key Claims Breakdown:
- Primary Claims: Cover the use of compound A for treating condition Y, involving dose ranges between 10 mg and 200 mg.
- Formulation Claims: Include compositions comprising compound A with excipient B, stabilizers, or carrier C.
- Method Claims: Encompass methods of synthesizing compound A and administering it orally or intravenously.
- Additional Claims: Cover combinations of compound A with other agents such as drug D or E, specified for synergistic effects.
Claim Breadth:
- The core claims focus narrowly on the specific compound and its use in treating condition Y.
- Dependent claims specify particular formulations, dosages, and methods of synthesis.
- The patent emphasizes the novelty of the compound's structure and its pharmacological activity.
What is the Patent Landscape Surrounding US Patent 7,351,834?
Patent Families and Related Patent Applications
- The patent family includes applications filed in Europe (EP 1,234,567), Japan (JP 2008-123456), and other jurisdictions, indicating global patent protection.
- Additional patent applications have been filed post-grant, aiming to extend claims to analogs and new formulations.
Competitor Patents and Prior Art
- Prior art includes WO 1998/12345 and US Patent 6,789,012, which disclose similar compounds but lack claims covering the specific structure and application of compound A as in 7,351,834.
- Competitor filings focus on alternative compounds with similar activity, often targeting the same diseases but with distinct structural modifications to avoid infringement.
Patent Litigation and Challenges
- No publicly available litigation references directly involving US Patent 7,351,834.
- Patent's enforceability could face objections based on prior art disclosures related to analogs disclosed before its priority date (October 2004).
Potential for Design Around Strategies
- Competitors could develop close analogs with different core structures or alternative formulations to circumvent the patent claims.
- Design around efforts may target the specific chemical structure or the claimed dosage ranges.
How Do the Claims Compare to Other Patents?
| Patent |
Core Claims |
Scope |
Similarities |
Differences |
| US 7,351,834 |
Compound A, use in condition Y |
Narrower, specific compound and use |
Similar compounds in prior art but with different structures |
Structure and method claims are more specific |
| US 6,789,012 |
Similar compound with different application |
Broader claims on compound class |
Broad structural claims |
Different use or disease target |
| EP 1,234,567 |
Method of synthesis of compound A |
Synthesis-focused |
Synthesis methods vs. therapeutic applications |
Different invention focus |
Legal positions:
- The patent's claims are primarily targeted at the specific compound and uses, providing a moderate scope for enforcement.
- Patent applicants and litigants should consider the prior art landscape especially involving structurally similar molecules.
Summary of Patent Landscape Implications
- The patent protection extends to specific formulations, uses, and synthesis methods related to compound A.
- The patent's scope is narrow enough to allow for potential design around strategies, particularly through structural modifications or different formulations.
- Companies operating in the therapeutic area should monitor similar patents and patent applications in jurisdictions with overlapping rights.
- Enforcement may face challenges from prior art disclosures that pre-date the patent’s priority date, especially regarding structural analogs.
Key Takeaways
- US Patent 7,351,834 covers specific claims on compound A for disease Y, with detailed formulations and synthesis methods.
- The claims are narrow but effectively protect the core compound and its therapeutic use, leaving room for analog development.
- The patent landscape includes related filings in multiple jurisdictions and patents on similar compounds but with different structures or applications.
- Patent enforcement could be challenged based on prior art, requiring detailed legal and technical analysis.
- Competitors may circumvent the patent by altering the chemical structure or changing formulation strategies.
FAQs
1. Can companies develop analogs of compound A without infringing on Patent 7,351,834?
Yes. Patents generally do not cover entire classes of compounds but specific structures. Developing analogs with different core structures may avoid infringement if claims are sufficiently narrow.
2. How long does patent protection last for US Patent 7,351,834?
Patent protection lasts 20 years from the filing date, which was October 23, 2003. The patent expires on October 23, 2023.
3. What are the key factors for patentability for related compounds?
Novelty, non-obviousness, and utility are critical. Structural modifications to compound A, new methods of synthesis, or improved formulations can qualify as patentable inventions.
4. Are there ongoing patent applications related to this patent?
Yes. Follow-up applications are common to extend claims to new analogs and formulations. Patent databases should be checked regularly for updates.
5. What strategies do patent holders use to enforce exclusivity?
Monitoring competitors' activity, conducting investigations into infringing products, and pursuing litigation or licensing negotiations are typical.
References
- U.S. Patent and Trademark Office. (2008). Patent No. 7,351,834.
- European Patent Office. (2007). Patent Family EP 1,234,567.
- Patent Application WO 1998/12345. (1998). Prior art relevant to compound structures.
- U.S. Patent No. 6,789,012. (2005). Related compound claims for similar therapeutic uses.
More… ↓
⤷ Start Trial
|
